P12 | SUBCUTANEOUS DARATUMUMAB (DARA) + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE WITH DARA + LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVE

Authors

Institutions

Publication Details

Journal
Haematologica
Published
2026-04-12
DOI
https://doi.org/10.3324/haematol.2026.s2.14037
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P12 | SUBCUTANEOUS DARATUMUMAB (DARA) + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE WITH DARA + LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVE

Pieter Sonneveld, M.A. Dimopoulos, H Quach, E. Antonioli et al.
Haematologica
Multiple Myeloma Research and Treatments
article

P12 | SUBCUTANEOUS DARATUMUMAB (DARA) + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE WITH DARA + LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVE

Pieter Sonneveld, M.A. Dimopoulos, H Quach, E. Antonioli, Xavier P Leleu, M. Beksaç, M Cavo, A Broijl, A. Perrot, P. J. Ho, H. Pei, H Einsele, S. Mangiacavalli, P. Rodríguez-Otero, C. Hulin, A. Belotti, M. Boccadoro, R.L. Carson, A. Sitthi-Amorn, Ph. Moreau
article en

Abstract

No abstract available for this paper.
HaematologicaVol. 111(s2)
Johnson & Johnson (United States) (US), Ankara University (TR), The University of Melbourne (AU), National and Kapodistrian University of Athens (GR), University of Pavia (IT), Royal Prince Alfred Hospital (AU), Centre Hospitalier Universitaire de Toulouse (FR), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT), Centre Hospitalier Universitaire de Poitiers (FR), Hôpital Cardiologique du Haut-Lévêque (FR), Universitätsklinikum Würzburg (DE), Clinica Universidad de Navarra (ES), Erasmus MC Cancer Institute (NL), University of Florence (IT), University of Turin (IT), University of Bologna (IT)
Good health and well-being
Openalex Percentile: Top 21%
Multiple Myeloma Research and Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

P12 | SUBCUTANEOUS DARATUMUMAB (DARA) + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE WITH DARA + LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVE — Pieter Sonneveld, M.A. Dimopoulos, et al. · Haematologica (2026) | TGRS Research Map | TGRS